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ABSTRACT 34 
 35 
Colorectal cancer (CRC), a disease of high incidence and mortality, exhibits a large degree of 36 
inter- and intra-tumoral heterogeneity. The cellular etiology of this heterogeneity is poorly 37 
understood. Here, we generated and analyzed a single-cell transcriptome atlas of 49,859 CRC 38 
cells from 16 patients, validated with an additional 31,383 cells from an independent CRC patient 39 
cohort. We describe subclonal transcriptomic heterogeneity of CRC tumor epithelial cells, as well 40 
as discrete stromal populations of cancer-associated fibroblasts (CAFs). Within CRC CAFs, we 41 
identify the transcriptional signature of specific subtypes (CAF-S1 and CAF-S4) that significantly 42 
stratifies overall survival in more than 1,500 CRC patients with bulk transcriptomic data. We also 43 
uncovered two CAF-S1 subpopulations, ecm-myCAF and TGFß-myCAF, known to be associated 44 
with primary resistance to immunotherapies. We demonstrate that scRNA analysis of malignant, 45 
stromal, and immune cells exhibit a more complex picture than portrayed by bulk transcriptomic-46 
based Consensus Molecular Subtypes (CMS) classification. By demonstrating an abundant 47 
degree of heterogeneity amongst these cell types, our work shows that CRC is best represented 48 
in a transcriptomic continuum crossing traditional classification systems boundaries. Overall, this 49 
CRC cell map provides a framework to re-evaluate CRC tumor biology with implications for clinical 50 
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Main 66 
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and a leading cause of 67 
cancer-related mortality worldwide1,2. Approximately 50% of patients experience disease relapse 68 
following curative-intent surgical resection and chemotherapy3,4. Despite the high incidence and 69 
mortality of advanced CRC, few effective therapies have been approved in the past several 70 
decades5. One barrier to the development of efficacious therapeutics is the biological 71 
heterogeneity of CRC and its variable clinical course6. While landmark studies from The Cancer 72 
Genome Atlas (TCGA) have defined the somatic mutational landscape within CRC, several 73 
studies have shown that stromal signatures, including fibroblasts and cytotoxic T cells, are likely 74 
the main drivers of clinical outcomes7–12. These findings suggest that the clinical phenotypes of 75 
CRC and by extension, its tumor biology, is shaped by a complex niche of heterotypic cell 76 
interactions within the tumor microenvironment (TME)8-12.  77 
 78 
Bulk gene expression analyses by several independent groups have identified distinct CRC 79 
subtypes13–15. Reflecting both the tumor and TME, an international consortium published the 80 
Consensus Molecular Subtypes (CMS), which proposed four distinct subtypes of CRC15. 81 
Unfortunately, the association between CMS  and meaningful therapeutic response to specific 82 
agents have shown inconsistent results across studies and CMS lacks a concordance between 83 
primary and metastatic CRC tumors, limiting its utility thus far in clinical decision making16–23. As 84 
a result, an improved CMS classification or an alternative classification system is required to 85 
improve clinical utility.  86 
 87 
To overcome the limitations of bulk-RNA sequence profiling, we utilized single-cell RNA 88 
sequencing (scRNA-seq) to more thoroughly evaluate the CRC subtypes at the molecular level, 89 
including within the context of the currently defined CMS classification. We dissected heterotropic 90 
cell states of tumor epithelia and stromal cells, including a cancer-associated fibroblast 91 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted February 7, 2021. ; https://doi.org/10.1101/2021.02.02.429256doi: bioRxiv preprint 
(CAF) population. The CAF population's clinical and prognostic significance became apparent 92 
when CAF signatures were applied to large, independent CRC transcriptomic cohorts.  93 
 94 
RESULTS 95 
We profiled sixteen primary colon tissue samples and eight adjacent non-malignant tissues (24 in 96 
total) using droplet-based, scRNA-seq. Altogether, we captured and retained 49,589 single cells 97 
after performing quality control for downstream analysis (Fig. 1a, supplementary table 1). All 98 
scRNA-seq data were merged and normalized to identify robust discrete clusters of epithelial cells 99 
(EPCAM+, KRT8+, and KRT18+), fibroblasts (COL1A2+), endothelial cells (CD31+), T cells 100 
(CD3D+), B cells (CD79A+), and myeloid cells (LYZ+) using canonical marker genes. Additionally, 101 
each cell type compartment was analyzed separately. Cluster v0.4.1 and manual review of 102 
differentially expressed genes in each subcluster were studied to choose the best cluster 103 
resolution without cluster destabilization (see methods)24. Cell population designation  was 104 
chosen by specific gene expression, and SingleR was also utilized for unbiased cell type 105 
recognition (see methods)25–28. 106 
 107 
In addition to cancer cells, we identified diverse TME cell phenotypes, including fibroblasts 108 
subsets (CAF-S1 and CAF-S4), endothelial cells, CD4+ subsets (naïve/memory, Th17, and 109 
Tregs),  CD8+  subsets (naïve/memory, cytotoxic, tissue-resident memory, and Mucosa-110 
Associated Invariant (MAIT) cells),  NK cells, innate lymphoid cell (ILC) types, B cell phenotypes 111 
(naïve, memory, germinal center, and plasma cells), and monocyte lineage phenotypes (C1DC+ 112 
dendritic cells, proinflammatory monocytes [IL1B, IL6, S100A8, and S100A9]), and  M2 polarized 113 
anti-inflammatory [CD163, SEPP1, APOE, and MAF]),  tumor-associated macrophages (TAMs) 114 
(Fig. 1b-d, Extended Data Figs. 1-3, and Extended Data Tables  1-4)25–28.  115 
 116 
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For validation, we additionally profiled 31,383 high-quality, single cells from an independent cohort 117 
using stringent criteria to corroborate our findings (see methods)29. Thus, a total of 81,242 high-118 
quality cells were profiled to produce a single-cell map of 39 colorectal cancer patients. The results 119 
of the primary CRC cohort (49,859 single-cells) are available at the Colon Cancer Atlas 120 
(www.websiteinprogress.com). 121 
 122 
Malignant colon cancer reveals tumor epithelial cell subclonal heterogeneity and 123 
stochastic behavior.  124 
 125 
We detected 8,965 tumor and benign epithelial cells (EPCAM+, KRT8+, and KRT18+) and, on 126 
reclustering, produced 17 epithelial clusters (designated C1 to C17) (Fig. 2a and Supplementary 127 
Table 2). Clusters were chiefly influenced by colonic epithelial markers, including those for 128 
stemness (LGR5, ASCL2, OLFM4, and STMN1), enterocytes (FABP1 and CA2), goblet cells 129 
(ZG16, MUC2, SPINK4, and TFF3), and enteroendocrine cells (PYY and CHGA) 130 
(Supplementary Fig. 2a and Supplementary Table 2). Tumor cells exhibited a high degree of  131 
de-differentiated state of plasticity possibly accounting for lasting cancer growth (Supplementary 132 
Fig. 2b)30. Each distinct tumor-derived cluster was mostly patient-specific, reflecting a high degree 133 
of inter-patient tumoral cell heterogeneity. In contrast, epithelial populations derived from non-134 
malignant tissue samples from multiple patients clustered together, a pattern observed in previous 135 
studies confirming both normal tissue homeostasis and limited sample batch effects (Fig. 2a)31,32. 136 
 137 
We next aimed to identify gene expression programs shared across these clusters using hallmark 138 
pathway analysis33. A strong overlap was observed for multiple pathways such as activation of 139 
inflammatory, epithelial-mesenchymal transformation (EMT), immune response, and metabolic 140 
pathways (Fig. 2b). Interestingly, high microsatellite instability (MSI-H) and microsatellite stable 141 
(MSS) CRC tumors, considered clinically separate entities, demonstrated similar pathway 142 
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program activation within the tumor epithelial populations. Some clusters also showed activation 143 
of unique pathways such as activation of apical junctions and angiogenesis (C6), hypoxia and 144 
fatty acid metabolism (C11) and Notch signaling and DNA repair (C14), among others. However, 145 
MSI-H tumors differed from MSS tumors based on immune cell infiltration (Extended Data Fig. 146 
1).  147 
 148 
Since intratumoral heterogeneity is recognized as a key mechanism contributing to drug 149 
resistance, cancer progression, and recurrence, we next focused on dissecting potential 150 
transcriptomic states to identify heterogeneity within each patient’s tumor34–37. We found that each 151 
tumor specimen contained 2-10 distinct tumor epithelial clusters (Fig. 2c). Gene set variation 152 
analysis (GSVA) was performed on cells from individual tumor samples and illustrated the sub-153 
clonal transcriptomic heterogeneity within each specimen (Supplementary Fig. 2c)38. Clusters 154 
identified in individual pathway analysis demonstrated the up- or down-regulation of crucial 155 
metabolic and oncogenic pathways between samples, suggesting wide phenotype variations 156 
between cells from the same tumor39.  157 
 158 
Given the evidence of intratumoral epithelial heterogeneity, we next performed trajectory 159 
inference using pseudotime analysis to identify potential alignments or lineage relationships  (i.e., 160 
right versus left-sided CRC), CMS classification, or MSI status  161 
(Fig. 2d)40,41. This analysis also served as a control for inter-patient genomic heterogeneity and 162 
provided an orthogonal strategy to confirm the transcriptomic trends we identified. We detected 163 
five molecular states (S1n/t to S5n/t) with malignant and normal epithelial cells intermixed along 164 
a joint transcriptional trajectory. This observation is consistent with prior studies demonstrating 165 
that CRC cells recapitulate normal colon epithelia's multilineage differentiation process as each 166 
transcriptional state’s pathway activation in both normal and tumor cells was related to normal 167 
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colon epithelial function of nutrient absorption or maintaining colon homeostasis (Supplementary 168 
Fig. 3 and Supplementary Table 3)42,43. 169 
 170 
Additionally, tumor cells showed upregulation of embryogenesis (S2t), consistent with previous 171 
findings that tumor cells revert to their embryological states in cancer development 172 
(Supplementary Table 4)44. Interestingly, there were no significant associations with anatomic 173 
location, CMS classification, or MSI status within our dataset or an independent dataset of 31,383 174 
single cells (Supplementary Fig. 4)29. Hence, in our analysis, CRC development mainly 175 
represents a hijacking of the normal epithelial differentiation program, coupled with the acquisition 176 
of  embryogenic pathways (Supplementary Fig. 3)45.  177 
 178 
CRC-associated fibroblasts in the tumor microenvironment exhibit diverse phenotypes, 179 
and specific subtypes are associated with poor prognosis.  180 
 181 
We next focused on CRC TME subpopulations. High-quality 819 fibroblasts were re-clustered into 182 
eight clusters, and then phenotypically classified into two major subtypes to assess for further 183 
CAF heterogeneity. These phenotypic subtypes were found to be immunomodulatory CAF-S1 184 
(PDGFRA+ and PDPN+) and contractile CAF-S4 (RGS5+ and MCAM+) (Fig. 3 and 185 
Supplementary Table 4)46. This fibroblast cluster dichotomy was also observed in the 186 
independent CRC patient scRNA-seq dataset of 31,383 cells (Supplementary Fig. 5)29. 187 
 188 
The CAF-S1 and CAF-S4 subtypes showed striking resemblances to the mCAF (extracellular 189 
matrix) and vCAF (vascular)  fibroblast subtypes, respectively, as previously described in a mouse 190 
breast cancer model47. Most clusters were found in multiple patients, albeit in varying proportions, 191 
signifying shared patterns in CAF transcriptomic programs between patients. Fibroblasts derived 192 
from MSI-H tumors were distributed similarly throughout these clusters.  193 
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CAF-S1 exhibited high chemokine expressions such as CXCL1, CXCL2, CXCL12, CXCL14, and 194 
immunomodulatory molecules including TNFRSF12A (Supplementary Fig. 6). Additionally, 195 
CAF-S1 expressed extracellular matrix genes including matrix-modifying enzymes (LOXL1 and 196 
LOX)47. To determine this population's functional significance, we compared the CAF-S1 197 
population transcriptomes to those described recently in breast cancer, lung cancer, and head 198 
and neck cancer48. We recovered five CAF subtypes, within the CAF-S1 population, including 199 
ecm-myCAF (extracellular; GJB+), IL-iCAF (growth factor, TNF and interleukin pathway; 200 
SCARA5+), detox-iCAF (detoxification and inflammation; ADH1B+), wound-myCAF (collagen 201 
fibrils and wound healing; SEMA3C), and TGFβ-myCAF (TGF-β signaling and matrisome; 202 
CST1+, TGFb1+), which were previously divided into two major subtypes: iCAF and myCAF (Fig. 203 
3b). Among these five subtypes, ecm-myCAF and TGFβ-myCAF are known to correlate with 204 
immunosuppressive environments and are enriched in tumors with high regulatory T lymphocytes 205 
(Tregs) and depleted CD8+ lymphocytes. Additionally, these subtypes are associated with 206 
primary immunotherapy resistance in melanoma and lung cancer48.  207 
 208 
The CAF-S4 population expressed pericyte markers (RGS5+, CSPG4+, and PDGFRA+), CD248 209 
(endosialin), and EPAS1 (HIF2-α),  that this particular CAF subtype is vessel-associated, with 210 
hypoxia potentially contributing to invasion and metastasis, as has been shown in another study 211 
47. CAF-S4 clustered into the immature phenotype (RGS5+, PDGFRB+, and CD36+) and the 212 
differentiated myogenic subtype (TAGLN+ and  MYH11+)(Fig. 3c and Supplementary Table 213 
4)49.   214 
 215 
Given the correlation between CMS4 and fibroblast infiltration, we next sought to test the 216 
existence of CAF-S1 and CAF-S4 signatures in bulk transcriptomic data and their association with 217 
clinical outcomes15. To this end, we interrogated and carried out a meta-analysis of eight 218 
colorectal cancer transcriptomic datasets comprising 1,584 samples. We detected a strong and 219 
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positive correlation between specific gene expressions characterizing each CAF subtype in CRC. 220 
We also confirmed the presence of CAF-S1 and CAF-S4 signatures in pancreatic 221 
adenocarcinoma (n=118) and non-small cell lung cancer (NSCLC, n=80) cohorts (Fig. 4) (see 222 
methods for datasets). The gene signatures were specific to each CAF-S1 and CAF-S4, thus 223 
confirming their existence in TME of CRC and other tumor types.  224 
 225 
We found high CAF-S1 and CAF-S4 signatures associated with poor median overall-survival 226 
(HR>1, p<0.05), irrespective of CMS subtypes in three independent CRC datasets 227 
(Supplementary Fig 7). Additionally, CAF signatures stratified the CMS4 subtype into high- and 228 
low-risk overall survival in all datasets, thus identifying additional heterogeneity and providing 229 
prognostication in this aggressive patient subgroup (Fig. 4b-d). Here, using scRNA-seq, we show 230 
for the first time that high CAF infiltration in CRC is associated with poor prognosis across all 231 
molecular subtypes, and which further stratifies the CMS4 subgroup into high and low-risk clinical 232 
phenotypes in CRC cohorts. 233 
 234 
Single-cell RNA sequencing reveals heterogeneity beyond Consensus Molecular Subtypes 235 
in colorectal cancers and offers therapeutic opportunities.  236 
 237 
The lack of association between tumor epithelia and CMS classification, as well as the survival 238 
differences between high- and low-risk CAF signatures across CRC molecular subtypes suggest 239 
CRCs are much more heterogeneous than the traditional classification systems have indicated 240 
(e.g. those systems defined by somatic alterations, epigenomic features, and bulk gene 241 
expression data)13,14,50,51.  242 
 243 
Among these the widely adopted CMS classification, which reflects both the malignant cell 244 
phenotypes and the TME, classified CRC into CMS1 (MSI immune), CMS2 (canonical), CMS3 245 
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(metabolic), and CMS4 (mesenchymal) subtypes  based on bulk transcriptomic signatures15. To 246 
test our hypothesis, we estimated every cell type fraction using single-cell data from eight pooled 247 
datasets (>1,500 samples) with a machine-learning algorithm, CIBERSORTx52. When we 248 
compared epithelial, immune, and stromal cell populations among the CMS subtypes, we did not 249 
detect a distinct pattern of tumor, immune, or stromal cell signatures across the different CMS 250 
subtypes. Each CMS subtype was enriched in these cell types in varying proportions but without 251 
a clear distinction between the four subtypes, suggesting a lack of clear separation among the 252 
CMS subsets at the single-cell resolution (Fig. 5a-b). Upon analysis of four independent bulk RNA 253 
datasets, there was significant discordance in terms of  cell phenotype enrichment with respect 254 
to each CMS subtype across the datasets  except CMS4 which had predominant stromal 255 
enrichment (Supplementary Figs. 8-11)53. These discordant results could be due to intra-patient 256 
CMS heterogeneity, intratumoral variation in tumor purity, stromal and immune cell infiltration, 257 
and CMS's inability to address tumor/TME-to-tumor/TME variability, among others54.  Thus, novel 258 
approaches that consider these factors are required to stratify patients for optimal biomarker and 259 
therapeutic development. 260 
 261 
Based on the above findings, we postulate that CRC is more accurately represented in a 262 
transcriptomic continuum previously proposed by Ma et al.55. The authors analyzed bulk 263 
transcriptomic data using a novel computational framework in which denovo, unsupervised 264 
clustering methods (k-medoid, non-negative-matrix factorization, and consensus clustering) 265 
demonstrated the existence of CRC in a transcriptomic continuum56–58. They further carried out 266 
principal component analysis and robustly validated two principal components, PC Cluster 267 
Subtype Scores 1 and 2 (PCSS1 and PCSS2, respectively). We reasoned that using single-cell 268 
data could deepen our understanding of how each cell phenotype contributes to the CRC tumor 269 
microenvironment using continuous scores that inform CRC diversity beyond binning CRC into 270 
traditional classifications.  271 
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 272 
We evaluated every cell fraction (epithelial, stromal, and immune components) from our data 273 
with the Ma et al. algorithm on eight pooled bulk transcriptomic datasets, focusing on PCSS1 274 
and PCSS2, since these were validated in the original study (Fig. 5c-d). On projecting single-275 
cell expression profiles on quadrants corresponding to each of the four CMS, we noted a lack of 276 
separation of all cell phenotypes between CMS subtypes suggesting that CRC exists in a 277 
transcriptomic continuum55.  278 
 279 
To test continuous scores reproducibility, we analyzed four bulk transcriptomic datasets 280 
separately; we found that transcriptional shifts were reproducible across datasets for all major cell 281 
types (Supplementary Figs. 8-11). The continuous scores showed no reliability in classifying 282 
CRC into immune–stromal rich (CMS1/CMS4) or immune-stromal desert (CMS2/CMS3) subtypes 283 
as proposed previously 20. Thus, confirming continuous scores rather than discrete subtypes may 284 
improve classifying CRC tumors and may explain tumor-to-tumor variability,  tumor/TME-to-285 
tumor/TME and TME-to-TME variabilities 55. Of note, CAF-S1 exhibited high PCSS1 and PCSS2 286 
scores across independent datasets, correlating with the CMS4 subtype. Thus, our analysis 287 
identified CAF-S1 as a cell of origin for biological heterogeneity in CMS4 subtypes associated 288 
with poor prognosis (Supplementary table 5).  289 
 290 
DISCUSSION 291 
In the present study, we evaluated the CMS classification of CRC that have been developed by 292 
bulk RNA-seq through single-cell resolution transcriptomic analysis. We find that stromal cells 293 
engender a more significant contribution to biological heterogeneity. Although previous studies 294 
employing bulk transcriptomics have demonstrated that the degree of stromal infiltration is 295 
associated with prognosis and a small scRNAseq study utilizing 26 fibroblasts demonstrated poor 296 
survival among CAF-enriched CRC tumors especially the CMS4 subtype. Here, using much larger 297 
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sample set of 1,182 high-quality fibroblasts, we identify the CAF-S1 subtype to be the cell of origin 298 
associated with poor prognosis across all CRC CMS subtypes and not just CMS4 59. Further, we 299 
developed a novel signature of CAF infiltration and demonstrate that CMS4 can be stratified into 300 
risk groups associated with good or poor median overall survival. These findings are significant 301 
since the CMS4 subtype, is primarily  stromal-driven and is enriched in more than 40% of 302 
metastatic CRC samples from patients with worse outcomes21. We also identified CAF-S1 303 
subtypes associated with certain biological functions in other cancers, including the ecm-myCAF 304 
and TGFβ-myCAF subtypes (responsible for immunotherapy resistance in NSCLC and 305 
melanoma), and CAF-S4s known to play a role in inducing cancer cell invasion48,49. Thus, 306 
targeting CAFs to remodel the tumor microenvironment may lead to improved and much-needed 307 
therapeutic development for metastatic CRC patients21,22.  308 
 309 
Targeting of CAFs in solid tumors is being explored in multiple clinical trials with variable results60–310 
62. Such studies likely failed to address CAF heterogeneity and their complex interactions with the 311 
other cells of TME. Our study suggests that CRC may be intricately entwined with the stroma, 312 
and therefore may be amenable to stromal targeted combinatoric approaches, including 313 
monoclonal antibodies that abrogate CAF-S1 function. In future studies, the treatment of CRC  314 
patients should involve stroma targeted therapies and take the above aspects into 315 
consideration60,63. The scRNA-seq or bulk-RNA-seq signatures corresponding to CAF-S1 and 316 
CAF-S4 may serve as suitable biomarkers for tumors that are reliant on this axis. Immunotherapy 317 
responses in MSS CRC, which comprise almost 95% of metastatic CRC, are lacking; CAF 318 
subpopulations within the TME may be suppressing immune responses in these tumors 64. Based 319 
on our analysis, we speculate that targeting CAF-derived chemokines and cytokines via 320 
biospecific antibodies, vaccines, or even cell-based therapies, may enhance current checkpoint 321 
blockade strategies60. Functional validation and clinical studies will be required to confirm the 322 
clinical utility of targeting these CAF populations in CRC. 323 
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 324 
More importantly, our study's single-cell resolution enables us to investigate whether tumor cell 325 
transcriptomes, and by extension, biological phenotypes, are the primary determinant of CMS 326 
classification. Based on our findings, it appears that bulk analysis may have been confounded by 327 
varying tumor microenvironment population enrichment, and that tumor cells within each patient 328 
do not segregate into static phenotypes but rather exhibit considerable plasticity. In contrast, the 329 
single-cell analysis uncovered the complex and mixed cellular-phenotypes among each cell 330 
specific subpopulation, which projected in a transcriptomic continuum across CMS subtypes. 331 
These findings were further supported by scRNA-seq CMS classification analysis that assigned 332 
each CRC sample to multiple CMS subtypes thereby suggesting CMS heterogeneity in each CRC 333 
tumor20,65. These findings may also explain why CMS-defined populations of tumors have not 334 
been readily observed in transcriptomic data from independent CRC cohorts21,53. Our data 335 
indicate that attempts to divide CRC phenotypes into the current discrete subtypes may 336 
undermine optimal patient stratification in the clinical trial setting. Intriguingly, by applying two 337 
independent algorithms, we demonstrate that CRC tumors and their ecosystems exist in a 338 
transcriptomic continuum and not only show tumor-to-tumor variability (as proposed by Ma et al.) 339 
but also demonstrate tumor/TME-to-tumor/TME transcriptional variability at the single-cell 340 
resolution55. The continuous scores are reproducible across transcriptomic datasets, thus 341 
allowing robust identification of patient subtypes. This may help to optimize CRC treatment in 342 
future studies.   343 
 344 
In conclusion, our study lends strong support to the tumor biology models proposed by Ma et al. 345 
(and other groups) and represents a conceptual shift in our understanding of CRC pathogenesis, 346 
clinical management, and therapeutic development. Future studies will need to consider tumor-347 
TME to tumor-TME heterogeneity which will be critical for optimizing biomarkers and treatment 348 
strategies for CRC. 349 
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METHODS 383 
 384 
Patient and tissue sample collection. Patients with resectable untreated CRC who underwent 385 
curative colon resection at Rush University Medical Center (Chicago, IL, USA) were included in 386 
this Institutional Review Board (IRB)-approved study. CRC specimens from 16 patients including 387 
nine Caucasian, six African American and one Asian patient with corresponding 8 adjacent normal 388 
tissue samples were processed immediately after collection at Rush University Medical Center 389 
Biorepository and sent for scRNA-seq.  Thus, our scRNA-seq atlas represent diverse patient 390 
population. The study was conducted in accordance with ethical standards and all patients 391 
provided written informed consent.  392 
 393 
Droplet based scRNA-seq - 10× library preparation and sequencing. Single-cell RNA 394 
sequencing (scRNA-seq) was performed using 10X Genomics Single Cell 5' Platform. Tumors 395 
and non-malignant samples were enzymatically dissociated (Miltenyi), filtered through a 70-396 
micron cell strainer, pelleted after centrifugation at 300 xg and resuspended in DAPI-FACS buffer 397 
(PBS, 0.04% BSA). Samples were sorted and viable singlets were gated on the basis of scatter 398 
properties and DAPI exclusion. Approximately 3000 cells were pelleted and resuspended in PBS, 399 
and cells underwent single cell droplet-based capture on 10X Chromium instruments according 400 
to the 10X Genomics Single Cell 5' Platform protocol. Transcriptome libraries post-fragmentation, 401 
end-repair, and A-tailing double-sided size selection, and subsequent adaptor ligation also 402 
followed the manufacturer’s protocol. Illumina NextSeq 550 was used for library sequencing and 403 
data were mapped and counted using Cellranger-v3.1.0 (GRCh38/hg38).  404 
 405 
scRNA-seq data quality control, gene-expression quantification, dimensionality reduction, 406 
and identification of cell clusters. Cell Ranger was utilized to process the raw gene expression 407 
matrices per samples and all samples from multiple patients were combined in R package (v3.6.3 408 
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2020-02-29] -- "Holding the Windsock"). Seurat package (v3.2.2) was used in this integrative 409 
multimodal analysis66. Genes detected in fewer than three cells and cells expressing less than 410 
200 detected genes were filtered out and excluded from analysis. In addition, cells expressing > 411 
25% mitochondria were removed. Cell cycle scoring was performed, (for the S phase and the 412 
G2M phase) and the predicted cell cycle phases were calculated. Doublet detection and any 413 
higher-order multiplets that were not dissociated during sample preparation were removed  via 414 
the DoubletFinder (v2.0.2) package using default settings67. Following quality control one non-415 
malignant colon sample (B-cac13) was discarded due to poor data quality. Finally, 49,859 cells 416 
remained and were utilized for downstream analysis. 417 
We adopted the general protocol described in Stuart et al. (2019) to group single cells into different 418 
cell subsets66. We employed the following steps: clustering the cells within each compartment 419 
(including the selection of variable genes for each dataset based on a variance stabilizing 420 
transformation [VST]), canonical correlation analysis (CCA) to remove batch effects among the 421 
samples, reduction of dimensionality, and projection of cells onto graphs 68,69. Principal 422 
component analysis (PCA) was carried out on the scaled data of highly variable genes70. The first 423 
30 principal components (PCs) were used to cluster the cells and to perform a subtype analysis 424 
by nonlinear dimensionality reduction (t-SNE) and to construct Uniform Manifold Approximation 425 
and Projection (UMAP) for cell embeddings71,72.  We identified cell clusters under the optimal 426 
resolution by a shared nearest neighbor (SNN) modularity optimization-based clustering method. 427 
We implemented the FindClusters function of the Seurat package, which first calculated k-nearest 428 
neighbors and constructed the SNN graph. We implemented the original Louvain algorithm 429 
(algorithm = 1) for modularity optimization. Additionally, we utilized Clustree (v0.4.3) and manual 430 
review for identifying the best clustering resolution24.  431 
 432 
Major cell type detection and data visualization. To identify all major cell types, we evaluated 433 
differentially expressed markers in each identity cell group by comparing them to other clusters 434 
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using the Seurat FindAllMarkers function. We used positively expressed genes with an average 435 
expression of >/= 2-fold higher in that subcluster than the average expression in the rest of the 436 
other subclusters. We used known marker genes, which have the highest fold expression in that 437 
cluster with respect to the other clusters. We also utilized SingleR ((v0.99.10, R Package), which 438 
leverage large transcriptomic datasets of well-annotated cell types and manual annotation  for 439 
cell-type identification31,73–75. Depending on the presence of known marker genes the clusters 440 
were grouped as: epithelial cells (EPCAM, KRT8, and KRT18), fibroblasts (COL1A1, DCN, 441 
COL1A2, and C1R), endothelial cells (CD31+), myeloid cells (LYZ, MARCO, CD68, and 442 
FCGR3A), CD4 T cells (CD4), CD8 T cells (CD8A and CD8B),  and  B cells (MZB1), 31,47,73,76–80. 443 
The cells were eventually assembled into DGE matrices within each compartment, containing all 444 
six cell types. 445 
 446 
Major-cell type subclustering and data visualization. Each major cell type, including epithelial 447 
cells, endothelial cells, T cells, B cells, myeloid cells, and fibroblasts was reclustered and 448 
reanalyzed to study each compartment at a higher resolution to detect granular cellular 449 
heterogeneity in CRC. Clustree (v0.4.3) and manual review were utilized for optimal cluster 450 
detection. For cell annotation of each cell type, we utilized published literature gene expression 451 
signatures and manual review of differential genes among clusters. Additionally, we again utilized 452 
SingleR (v0.99.10, R Package) for unbiased cell annotation. Interestingly, reclustering of major 453 
compartments individually also detected clusters expressing hybrid markers as well as cell 454 
clusters expressing markers from distinct lineages (such as T cell clusters expressing B cells); 455 
these were removed and excluded for further analysis. We utilized UMAP for visualization 456 
purposes. For validation, we analyzed 65,362 cells from 23 patients and applied the same quality 457 
control metrics as outlined  above,  retaining  31,383 high-quality single cells for further analysis29.  458 
These high-quality cells were analyzed utilizing the same pipelines and parameters as that for our 459 
primary cohort (Supplementary Figs. 4-5 and 12-13).  460 
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The InferCNV (v1.2.1) package was used with default paramets  to identify the evidence for 461 
somatic large-scale chromosomal copy number alteration in epithelial cells (EPCAM+, KRT8+, 462 
KRT18+)81.  Non-malignant epithelial cells were used as the control group. 463 
 464 
Trajectory analysis. We used Monocle v.2 (v2.14.0), a reverse graph embedding method to 465 
reconstruct single-cell trajectories in tumor and non-malignant epithelium82. In brief, we used UMI 466 
count matrices and the negbinomial.size() parameter to create a CellDataSet object in the default 467 
setting. We grouped projected cells on UMAP in default settings for visualization of monocle 468 
results. We defined the cumulative duration of the trajectory to show the average amount of 469 
transcriptional transition that a cell undergoes as it passes from the starting state to the end state. 470 
The cells were also ordered in pseudotime to explain the transition of cells from one state to 471 
another. 472 
 473 
Pathway- Gene set variation analysis (GSVA). Pathway analysis was performed on the 50 474 
hallmark gene sets downloaded from Molecular Signatures Database (v7.2). We used GSVA 475 
(v1.34.0),  a non-parametric, unsupervised method to estimate the gene set variations and 476 
evaluation of pathway enrichment, and pathway scores were calculated for each cell using 477 
standard settings 33,38. 478 
  479 
DNA and bulk RNA library construction. DNA and bulk RNA sequencing was performed as 480 
previously described83. One hundred nanograms of DNA from each tumor was mechanically 481 
sheared to an average size of 200 bp. Using the KAPA Hyper Prep Pack, DNA libraries were 482 
packed, hybridized into the xT probe package, and amplified with the KAPA HiFi HotStart 483 
ReadyMix. For uniformity, each sample needed to have 95% of all targeted base pairs sequenced 484 
to a minimum depth of 300x. One hundred nanograms of RNA per tumor sample was heat 485 
fragmented to a mean size of 200 base pairs in the presence of magnesium. Using random 486 
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primers, the RNA was used for first-strand cDNA synthesis, followed by second-strand synthesis 487 
and A-tailing, adapter ligation, bead-based cleanup, and amplification of the library. After library 488 
planning, the IDT xGEN Exome Test Panel was hybridized with samples. Streptavidin-coated 489 
beads and target recovery were carried out, accompanied by amplification using the KAPA HiFi 490 
library amplification package. The RNA libraries were sequenced on an Illumina HiSeq 4000 using 491 
patterned flow cell technology to achieve at least 50 million reads. 492 
 493 
Detection of somatic variation on DNA sequencing data. The tumor and normal FASTQ files 494 
were paired. For quality management measurement, FASTQ files were evaluated using FASTQC 495 
and matched with Novoalign (Novocraft, Inc.)83,84. SAM files were generated and converted to 496 
BAM files. The BAM files were sorted, and duplicates were marked. Single nucleotide variations 497 
(SNVs) were called after alignment and sorting. For discovery of copy number alterations, the de-498 
duplicated BAM files and the VCF generated from the variant calling pipeline were processed to 499 
computate read depth and variance of heterozygous germline SNVs between the tumor sample 500 
and normal sample. Binary circular segmentation was introduced and segments with strongly 501 
differential log2 ratios between the tumor and its comparator were chosen. From a combination of 502 
differential coverage in segmented regions and estimation of stromal admixture provided by 503 
analysis of heterozygous germline SNVs, an estimated integer copy number was determined  504 
  505 
Microsatellite instability status. Probes for 43 microsatellite regions were developed using 506 
Tempus xT assay83. Tumors were categorized into three groups by the MSI classification 507 
algorithm as described by Tempus: microsatellite instability-high (MSI-H), microsatellite stable 508 
(MSS) or microsatellite equivocal (MSE). MSI screening for paired tumor-normal patients used 509 
reads mapped to the microsatellite loci with at least 5 bps flanking the microsatellite. The sample 510 
was graded as MSI-H if there was a >70% chance of MSI-H classification. If the likelihood of MSI-511 
H status was 30-70%, the test findings were too ambiguous to interpret and those samples were 512 
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listed as MSE. If there was a <30% chance of MSI-H status, the sample was called MSS. 513 
Additionally, IHC results were used to classify tumors into MSS or MSI molecular subtypes. Both 514 
of these modalities were concordant and produced the same results. 515 
 516 
Bulk RNA-seq and microarray analysis. We downloaded and pooled eight colorectal gene 517 
expression datasets (GSE1306785, GSE1329485, GSE1433386, GSE1753687, GSE2091688, 518 
GSE3311389, GSE3589690, and GSE3958214), a  pancreatic  cancer dataset (GSE6216591) and 519 
a non-small cell lung cancer dataset (GSE3353292)  to validate our findings from the single cell 520 
compartments by deconvoluting the bulk gene expression profiles into pseudo single-cell 521 
resolutions. We used Affy (v1.64.0) for the data analysis and for exploration of Affymetrix 522 
oligonucleotide array probe level data93. Batch correction was carried out using  the 523 
removeBatchEffect (v3.42.2) function of the LIMMA program and CMScaller for the CMS 524 
classification (see below)94. Three datasets (GSE1753687, GSE3311389, and GSE3958214) were 525 
utilized for clinical outcome analysis94,95. 526 
 527 
Correlation patterns in bulk gene expressions for CAF compartments. To identify the top 528 
correlated CAF-marker genes within the combined eight CRC datasets, four bulk CRC gene 529 
expression sets individually, pancreas cancer and lung cancer datasets. We first transformed the 530 
bulk gene expression sets with log2 transformation. Next, marker genes with an average log2 531 
FC>/= 0.5 and p<0.05 obtained from the single cell data of CAF-S1 and CAF-S4 compartments 532 
were separately intersected with the bulk gene expression sets. Genes with an average 533 
Spearman correlation score greater than 0.8 were kept as the CAF signatures within the bulk 534 
gene expression. Heatmaps illustrating the correlation patterns within and between the CAF 535 
compartments were prepared with the heatmap.2 function from ggplot package (v3.1.1) utilizing 536 
the Pearson correlation coefficient. Heatmaps illustrating the correlation patterns within and 537 
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between the CAF compartments were prepared using the ggplot package (v3.1.1) utilizing the 538 
Pearson correlation coefficient96. 539 
 540 
 The Cox proportional hazard regression model was used to examine the significance of 20 cell 541 
types from scRNA-seq in bulk expression data. Each cell type's marker genes with an average 542 
logFC>1 and adjusted P<0.05 were intersected with the bulk expression datasets separately.  We 543 
only kept the marker genes with a high correlation with each other in bulk, which provides an 544 
average correlation score of > 0.8. The average bulk expression of each cell type's remaining 545 
marker genes was calculated and used in the hazard regression model as the representative of 546 
this cell type. For analysis of relationships with patient outcome, univariate models were 547 
calculated using Cox proportional hazard regression (coxph function from survival R package)97. 548 
 549 
Deconvoluting public bulk gene expression profiles into pseudo single-cell expressions. 550 
We used CIBERSORTx v1 to estimate composition of various cell populations in pooled eight  551 
microarray datasets52.  Signature gene matrices were created using the expression profiles of 552 
49,859 cells as the reference single cell profile. We ran the ‘hires’ module with default parameters 553 
except for the ‘rmbatchBmode,’ and the bulk-mode batch correction argument was set to true. 554 
After the deconvolution process, we normalized the gene expressions according to the cell 555 
fractions in each sample and calculated each gene’s Z-transformed expression values. The 556 
average normalized expression of each cell type across all samples was plotted with the 557 
heatmap.3 R function of the GMD package (v0.3.3)98. A signature matrix highlighting marker 558 
genes of the different cell types was prepared with a heatmap.2 R function of ggplot (v3.1.1). We 559 
also applied the same parameters to deconvolute GSE1433386, GSE1753687, GSE3311389, and 560 
GSE3958214 datasets individually.  561 
  562 
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Consensus molecular subtyping of colorectal cancer (CMS Classification). We used R 563 
package CMScaller(v0.9.2), a nearest template prediction (NTP) algorithm, for the classification 564 
of gene expression datasets95. We set the permutation number to 1000 to predict the CMS classes 565 
of the samples in the GEO datasets with a p-value < 0.05.  We ran CMScaller with default 566 
parameters. 567 
 568 
Continuous subtype discovery using scRNA-seq analysis. Bulk mRNA expression profiles of 569 
the combined and batch adjusted eight GEO datasets (GSE1306785, GSE1329485, GSE1433386, 570 
GSE1753687, GSE2091688, GSE3311389, GSE3589690, and GSE3958214),  composed of 1584 571 
samples in total, were deconvoluted into the pseudo single-cell expression profiles via 572 
CIBERSORTx utilizing the expression data consisting of 2o different cell types from our scRNA-573 
seq dataset52. We transformed the deconvoluted expression matrix with log2 transformation. The 574 
principal components cluster subtype scores (PCSSs) of the CMS subtypes among the 1584 575 
samples, were determined separately for each cell type using an algorithm published by Ma et 576 
al55. To obtain the PCSSs, the average loading vectors were used. The results obtained for 20 577 
cell types were projected on the first two PCSSs (PCSS1 and PCSS2) as they were validated by 578 
Ma et al. in their analysis using 18 datasets. We also analyzed four datasets (GSE1433386, 579 
GSE1753687, GSE3311389, and GSE3958214) to  independently confirm reproducibility of 580 
continuous scores.  581 
 582 
Statistics and reproducibility. All statistical analyses and graphs were created in R (v3.6.3) and 583 
using a Python-based computational analysis tool. Schematic representations were made using 584 
the Inkscape (https://inkscape.org/) software. Dim plots, bar plots and box plots were generated 585 
using the dittoSeq (v1.1.7) package with default parameters99. Violin plots were generated using 586 
the patchwork (v1.1.0) package and ggplot2 (v3.3.2) package in R with default parameters. 587 
Heatmaps were generated using Morpheus.R with default parameters100,101. ANOVA and pair-588 
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wised t-tests for the CMS classes across the deconvoluted expression profiles were performed in 589 
R using the ggpubr R (v0.4.0) package102. The Box and Whisker plots were generated using the 590 
boxplot function of the R base package at default parameters. The mean of the log2 transformed 591 
deconvoluted expression value of the samples in each CMS group was demonstrated with a 592 
horizontal straight line within each box.  The length of a boxplot corresponds to the interquartile 593 
range (IQR), which is defined as the range between the first and third quartiles (Q1 and Q3), 594 
whereas the whiskers are the upper and lower extreme values of the data (either data's extremum 595 
values, or the Q3+1.5*IQR and Q1-1.5*IQR values, whichever was less extreme).  596 
 597 
Survival analysis. Survival curves were obtained according to the Kaplan-Meier method survfit 598 
(v3.2-7), and differences between survival distributions were assessed by Log-rank test. The 599 
patients were divided into two groups (high/poor and low/good risk) according to their median 600 
expression values (survminer (v0.4.8)). The surv_cutpoint function uses the maximally selected 601 
rank statistics and implements standard methods for the approximation of the null distribution of 602 
maximally selected rank statistics (maxstat (v0.7-25). 603 
 604 
The proportional hazard assumption was tested to examine the fit of the model for survival of the 605 
samples in four GEO datasets (GSE1433386, GSE1753687, GSE3311389, and GSE3958214) with 606 
respect to the deconvoluted bulk mRNA expressions. For analysis of the relationships with patient 607 
outcome, multivariate models were calculated using the Cox proportional hazard regression 608 
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Figure 1. Identification and clustering of single cells. a, Workflow of sample collection, 856 
sorting, and sequencing (methods contain full description for each step). b, UMAP 857 
characterization of the 49,859 cells profiled. Coloring demonstrates clusters, tumor vs. non-858 
malignant sample origin (condition), and individual sample origin. c, Identification of various cell 859 
types based on expression of specified marker genes. d, Characterization of the proportion of 860 
cell types identified in tumor vs. non-malignant tissue, sidedness (right vs. left), microsatellite 861 
instability (MSI) status, single-cell Consensus Molecular Subtypes (scCMS) classification, 862 
Consensus Molecular Subtypes (CMS) of bulk RNA-seq data, and origin of sample. The 863 
transcription counts of tumor and normal tissue cell types are demonstrated at the bottom with 864 
boxplot representation. The graph represents total clusters and cell types identified after re-865 
clustering of each cell compartment depicting global heterogeneous landscape of colorectal 866 
cancers.867 
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Figure 2. Reclustering and characterization of the epithelial compartment. a, UMAP of 869 
tumor and non-malignant epithelial reclustering demonstrating 17 distinct clusters. b, Heatmap 870 
of Hallmark pathway analysis within the epithelial cell compartment. c, Bar chart representation 871 
of cell proportions by sample, tissue type, MSI status, colonic location of sample, scCMS score, 872 
and bulk CMS score. d, Trajectory analysis of cells colored by colonic location, scCMS, MSI 873 
status, and bulk CMS status.874 
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2 
Figure 3. Fibroblast clusters in colon and colorectal tumors. a, UMAP of 819 fibroblasts 876 
colored by distinct clusters, CAF status, tissue status and origin of sample.  UMAP fibroblasts 877 
colored by specific CAF-S1 subtypes. b, UMAP color-coded for marker genes for five CAF-S1 878 
subtypes as indicated. c, Heatmap showing the variable expression of fibroblast specific marker 879 
genes across CAF-S1, CAF-S4, and normal fibroblasts. d, Heatmap of Hallmark pathway 880 
analysis of CAF-S1, CAF-S4, and normal cluster. 881 
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4 
Figure 4. Correlation of CAF-S1 and CAF-S4 gene profiles across human bulk 883 
transcriptomic data. a, Pearson’s correlation of genes from CAF-S1 and CAF-S4 profiles in 884 
colorectal cancer (n= 1584; CAF-S1 and CAF-S4 r > 0.8), pancreatic cancer (n= 118; CAF-S1 r 885 
= 0.70, CAF-S4 r= 0.60), non-small cell lung cancer (n = 80; CAF-S1 r  = 0.69, CAF-S4 r = 886 
0.67). b-d, Pearson correlation plots, Kaplan-Meyer survival curves, and bar plots of CMS 887 
status assessing CAF expression in individual CRC datasets. Plots b-c are generated from 888 
single GEO datasets; GSE17536 (n = 177), GSE39582 (n= 585) and GSE33113 (n= 96), 889 
respectively. Note: High CAF-S1 and CAF-S4 gene signatures are associated with poor survival 890 
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Figure 5. Average cell type abundance from eight pooled CRC datasets and sorted by 915 
bulk CMS status. a, Boxplots show the distribution of cell types within tumors with varying CMS 916 
status. The whiskers depict the 1.5 x IQR. The p-values for one-way ANOVA are shown in the 917 
figure. b, Deconvolution heatmap of different cell types by average expression using 918 
CIBERSORTx demonstrating cell type distribution (based on individual datasets) within each 919 
CMS category. c, All 20 cell types show no to little separation reported by CMS. d, All cell types 920 
projected on four quadrants representing CMS1-4 using PCSS1 and PCSS2 scores. Markers 921 
are colored by the bulk CMS status. Note that the cell types largely form a continuum along 922 
CMS status and are not clustered in discrete quadrants separate from one another. Cells are 923 
colored by bulk CMS status accordingly to origin of sample. 924 
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